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Kidney cancer, although relatively rare when compared to
other malignancies, occurs not uncommonly in patients with
renal disease and is often discovered incidentally during the
initial nephrologic work-up, or by the savvy clinician who is
familiar with the paraneoplastic signs. While surgical
approaches are generally curative when the disease is
confined to the kidney, one-third of the cases that present in
the metastatic form and require conventional medical
therapy are associated with a truly dismal patient survival
rate. In light of the emerging knowledge of the molecular
mechanisms of kidney cancer oncogenesis, several novel and
promising therapeutic approaches are emerging. In this
review, we summarize the current state of kidney cancer
diagnosis and therapy, as well as some of the novel
treatments that capitalize on those newly elucidated
molecular pathways that are deranged in this disease.
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While generally considered to be under the purview of
urologists, kidney cancer is not uncommonly discovered in
the modern practice of nephrology. Often found incidentally
during nephrologic screening procedures undertaken during
the work-up of acute or chronic kidney disease or hematuria,
kidney cancer (also known as renal cell carcinoma (RCC)) is
sometimes called ‘the internist’s tumor’ because it is often the
presence of a variety of disparate and truly fascinating
systemic signs of the disease that lead to the diagnosis by the
astute clinician. Therefore, the knowledge of such presenting
signs and symptoms is crucial for the practicing nephrologist
in order not to miss this disease the prognosis of which is
indeed dismal when discovered late in its course.
While kidney cancer represents a heterogeneous group
of diseases, most of the current research efforts are focused
on clear-cell renal carcinoma, which represents 75%
of all human renal epithelial neoplasms. From a research
perspective, kidney cancer is one of the more interes-
ting malignancies, since many of the basic molecular
pathways leading to oncogenic transformation have
been worked out. This has resulted in a flurry of new
potential ‘designer therapies’, some already in clinical trials
and others still in the pipeline. In addition, the molecular
biology of its association with the inherited disorder, von
Hippel–Lindau (VHL) disease and the presence of mutations
in a ‘survival’ pathway that work to the tumor’s advantage
have also led to novel approaches for identifying drugable
signaling pathways.
Unfortunately, despite substantial knowledge of its
genetics and identification of key signaling pathways, both
incidence and mortality of kidney cancer have steadily
worsened over the last several decades. Surgical resection is
considered to be the only effective treatment in the localized
form of kidney cancer, yet, even in this case, 20–30% of
patients will experience recurrence of the disease.1 Owing to
the depressing survival statistics discussed below, translation
of the basic research in this disease to the bedside is urgently
needed from both the nephrologic as well as the urologic
communities. In this review, the clinical manifestations, basic
biology and new directions of research in kidney cancer
therapeutics will be discussed; the latter is clearly an evolving
(though promising) work in progress.
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EPIDEMIOLOGY, CLINICAL PRESENTATION AND IMAGING
Kidney cancer is considered an ‘orphan cancer’ by the
National Cancer Institute since there are fewer than 200 000
new diagnoses per year in the US. For this reason, research
funding as well as interest in basic research in kidney cancer
are lacking when compared to its more prevalent oncologic
cousins such as breast and colon cancer; yet as many 11 000
people, many of whom are our chronic kidney disease
patients, die of this disease yearly in the US.2 According to
the National Cancer Institute Surveillance, Epidemiology and
End Results (SEER) data (www.seer.cancer.gov), the 5-year
survival of patients with localized disease is 89% (represent-
ing 54% of all patients), in regionally advanced disease 61%
and in metastatic disease an alarming 9%. While accounting
for only 3% of cancer incidence and mortality in the US,
kidney cancer is the sixth leading cause of cancer death in the
US and its incidence, as well as its associated mortality rates,
is increasing at an alarming rate (Figure 1), especially among
African-American male patients.3 Identified risk factors for
the development of renal carcinoma are cigarette smoking,
hypertension, obesity and family history, yet the most
prevalent association between RCC and a genetic abnorm-
ality occurs in VHL disease, in which approximately 40% of
patients are so affected. The recent identification of the
genetic abnormality in VHL patients has led to the
elucidation of the molecular pathways leading to RCC
pathogenesis, which form the basis of novel therapeutic
efforts, as will be discussed in detail below. Acquired cystic
disease, a frequent occurrence in the end-stage renal disease
population, is also associated with a high incidence of RCC,4
but the high prevalence of hypertension in this population is
a confounding risk factor.
It is possible that at least part of the upsurge in RCC
diagnosis is due to the increased use of imaging techniques
used when working up chronic kidney disease patients. In
this age of sophisticated screening tests, employed routinely
in even the milder cases of renal insufficiency (such as kidney
ultrasonography), the classic Virchow triad of gross hema-
turia, flank pain, and flank mass is now rarely seen as the
presenting findings. Owing to the incidental findings of RCC
when evaluating patients for renal disease, only 10% of
patients present with this triad, and it is usually a sign of
advanced disease.1 In several recent studies, 15–48% of RCC
cases were diagnosed during work-up of an unrelated
disorder;5,6 at the time of presentation, as high as 25–30%
of patients have metastatic disease, which puts them in the
dire prognostic category.
From an internist’s perspective, the most noteworthy
aspect of RCC is its association with paraneoplastic
syndromes, caused by the ectopic secretion of hormones or
hormone-like substances. Such syndromes, which are often
the only clues to early diagnosis (and thus need to be
recognized by the nephrologist), occur in up to 30% of
patients (Table 1). In a retrospective study of a series of 1046
patients who underwent nephrectomy for RCC, from the
University of California Los Angeles database, anemia (52.1%
of cases), hematuria (35.2% of cases), and hepatic dysfunc-
tion (31.5% of cases) were the most common presenting
signs and symptoms.7 Therefore, keeping a high index of
suspicion when these disparate phenomena are observed in
patients with normal as well as impaired renal function is
essential, since, early diagnosis (when the tumor is confined
to the kidney) is the key to effective treatment and patient
survival.
In the setting of the nephrology clinic, most RCCs are
discovered incidentally when patients are being evaluated for
renal insufficiency, proteinuria, or hematuria in the absence
of other symptoms. In these situations, renal imaging will
reveal a solid mass or a complex cyst. While work-up and
treatment of a solid renal mass is relatively straightforward
(see below), further evaluation of complex cysts is more
elaborate. Such cysts, which contain calcifications, septations
mural nodules, as well as internal debris, may often be
malignant. There exists a Bosniak classification system of
such lesions, discussion of which is beyond the scope of this
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Figure 1 | Incidence of and mortality from kidney cancer,
1975–2001. Both incidence and mortality from kidney cancer have
steadily increased during this period in both sexes (from Tuma,47
used with permission).
Table 1 | Paraneoplastic syndromes and presenting signs
associated with RCC
Syndrome or sign % incidence
‘Classic’ triad 10
Anemia 30–50
Hematuria 35
Weight loss 33
Fever 25
Hypertension 20
Abnormal liver function tests 10–30
Hypercalcemia 5–10
Erythrocytosis 3
Neuromyopathy 3
Amyloidosis 2–5
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review but is generally known to radiologists reading
ultrasounds, which assigns the likelihood of malignancy to
given cyst characteristics.8 The special case of acquired cystic
kidney disease, due to progressive renal insufficiency and
therefore seen frequently in the nephrology clinic setting, is a
situation in which malignant cyst transformation commonly
occurs and is frequently overlooked; this disease accounts for
80% of renal neoplasms seen in uremic and end-stage renal
disease patients.9 Since cyst vascularity is often a sign of
cancer (due to the high vascular endothelial growth factor
(VEGF) secretion of these tumors, discussed below), further
imaging, utilizing a modality that recognizes the vasculature
(such as computed tomography or magnetic resonance
imaging/magnetic resonance angiography), may be required.
Delayed computed tomography can confirm vascularity in a
suspect renal lesion and help differentiate it from a high-
density cyst;10 dynamic contrast-enhanced magnetic reso-
nance imaging has been shown to be especially useful for the
identification of small malignant lesions (p3.0 cm), which
often escape detection by other methods.11 However, recent
improvements in ultrasound that visualizes vascularity, such
as enhanced gray-scale and color Doppler, may ultimately
make ultrasonography more sensitive in differentiating cysts
from renal tumors.12 The goal, of course, in all of these
imaging modalities is to identify renal cancers before they
leave the safe confines of the kidney capsule.
KIDNEY CANCER: A HETEROGENEOUS DISEASE
Kidney cancer is not a single disease, but rather a
heterogeneous group of at least five different histologic
types. This malignancy occurs in a sporadic noninherited
form as well as a hereditary form, the latter associated with
distinct, known genetic mutations and thus identifiable
diseases or syndromes (Figure 2). By far the most common
histologic type is clear cell, comprising 75% of all renal
cancers;13 this subtype will be discussed in more detail in this
review. The VHL gene is mutated both in hereditary RCC as
well as in most cases of sporadic clear-cell RCC, the former
due to a germline mutation of one allele and loss of
heterozygosity of the other, and the latter due to acquired
mutations in both alleles.14 As will be discussed below, the
VHL gene encodes a protein (pVHL), which is important for
regulating the tissue response to hypoxia in kidney as well as
other cancers, and thus the hyperangiogenic phenotype of
this disease.
Mutation of the gene which is responsible for hereditary
papillary renal cell carcinoma was found to be the proto-
oncogene c-Met, a receptor tyrosine kinase. Renal tumors in
the Birt–Hogg–Dube´ syndrome are associated with cutaneous
fibrofolliculoma, pulmonary cysts and pneumothorax;
Birt–Hogg–Dube´ gene is located on chromosome 17. In
hereditary leiomyomatosis renal cell carcinoma syndrome,
patients develop cutaneous and uterine leiomyoma and renal
cancer of the papillary type 2 variety; the genetic mutation in
this disease lies in the fumarate hydratase (FH) gene,
although it is unclear how this Krebs cycle enzyme is
associated with neoplasia.
Since each of the separate pathologic types of RCC has a
different oncogenic mechanism, there exist distinct disease-
specific approaches to therapy, many of which capitalize on
the molecular pathway(s) affected.15 Designer drugs and/or
gene therapeutic approaches, as will be discussed later in this
review, can in theory be tailored to the malignancy in
question; thus, it is essential to obtain a tissue diagnosis
before any treatment regimen is begun.
TARGETING MOLECULAR PATHWAYS
It has historically been noted that tumors in patients with
VHL disease, such as clear-cell RCC, are highly angiogenic
and are associated with high levels of the proangiogenic
factor VEGF.16 In addition, many of these tumors cause
paraneoplastic erythrocytosis through ectopic secretion of
erythropoietin,17 further contributing to the angiogenic
phenotype. While the transcription of VEGF and erythro-
poietin genes is a phenomenon characteristic of hypoxic
tissues (and are thus referred to as hypoxia-inducible genes,
such as hypoxia-inducible factor or HIF), the molecular basis
of the VHL connection to the angiogenic findings was at first
not obvious.16 Furthermore, while VHL disease accounts for
only 2% of all kidney cancers, it has been known that there
exist inactivating mutations in the VHL gene in 80% of
sporadic clear-cell RCCs;14,18 thus, a mysterious link had
been postulated between the VHL gene product and
angiogenesis, but it was not until the landmark paper by
Maxwell et al.19 that this mystery was solved by the
identification of an HIF/VHL connection, discussed below.
Given their logarithmically increasing mass and density,
‘healthy’ malignant tumors require oxygen in order to grow
and flourish, much to the detriment of the patient who is
hosting them. Although small tumors (1–2 mm in diameter)
can receive all the required nutrients by diffusion, further
growth is dependent on the formation of an efficient blood
delivery system.20 ‘Successful’ tumors, therefore, progres-
sively grab more than their fair share of oxygen and assorted
nutrients through the creation of a network of microvessels.
Type Clear cell Type 1 Type 2 Chromophobe Oncocytoma
Gene mutation VHL Met FH
Papillary
Disease VHL HPRC HLRCC Birt–Hogg–Dubé
Birt–Hogg–Dubé
Frequency 75% 5% 10% 5% 5%
VHL=von Hippel–Lindau disease;
HPRC=hereditary papillary renal carcinoma syndrome;
HLRCC=hereditary leiomyomatosis renal cell carcinoma syndrome.
Figure 2 | Human kidney epithelial neoplasms. While clear-cell RCC
is the most common histologic type, there exist rarer forms each
associated with known genetic mutations and corresponding
syndromes.
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These highly angiogenic cancers have evolved myriad
techniques to increase their blood supply through the process
of tumor angiogenesis, and perhaps more importantly to
RCC, such angiogenesis is a critical step for tumors to
become metastatic.21
While a full account of the process of tumor angiogenesis
is beyond the scope of this review, there are several signaling
proteins important to the genesis of RCCs that relay a
hypoxia signal from tumors to the angiogenic machinery.
Chief among these is the HIF group of transcription factors
consisting of a regulatable subunit and a constitutively
expressed b-subunit. In normal cells, HIF-1a subunits
accumulate under hypoxic conditions, combine with
HIF-1b subunits and cause accumulation of proteins, which
ultimately provide valuable protection from the effects of
chronic hypoxia. Activated HIF leads to the transcription of
several genes whose corresponding proteins are important for
blood vessel growth and oxygen delivery, such as VEGF,
erythropoietin, platelet-derived growth factor (PDGF) and
transforming growth factor-a (Figure 3). In normal tissues,
which become transiently hypoxic, this is an adaptive
response; it is easy to envision how this response could go
awry and cause the appearance of hypoxia-repairing proteins
when they should not be there, as in the case of kidney
tumors lacking functional pVHL.
It was known that RCCs are highly angiogenic tumors
characterized by aberrant expression of HIF-related proteins,
but what was the link to VHL disease? Maxwell et al.19 solved
this mystery by showing that, in pVHL-deficient cells, (1)
pVHL and HIF can physically associate, and (2) cells
defective in pVHL are unable to degrade HIF-a under both
normoxic and hypoxic conditions. pVHL-dependent HIF-1a
degradation is inhibited by deferoxamine in vitro (a finding
that comes in handy when designing experiments), but
hypoxia stabilizes HIF-1a in a completely different (and as yet
unknown) manner,19 since in the latter case pVHL–HIF-1a
complexes remain intact (Figure 3).
In any case, the absence of pVHL, as in VHL-deficient
RCCs occurring in VHL disease, has continuous HIF-1a
activation (due to lack of degradation) and pVHL-deficient
RCCs behave as though they are constitutively hypoxic even
though they are, in fact, flush with oxygen. Through the
activation of HIF, these tumors signal their surroundings to
increase production of angiogenic growth factors, such as
VEGF, whose function it is to carry blood, and hence oxygen,
to hypoxic tissues (Figure 3). In this manner, VHL can be
considered a classical tumor suppressor gene since its
inactivation leads to cancer, and HIF can be considered a
somewhat unorthodox oncogene as it can indirectly drive
uncontrolled growth through exuberant angiogenesis. These
findings not only explain the high angiogenic phenotype of
tumors associated with VHL disease but also suggest possible
therapeutic approaches involving the inhibition of HIF.
Furthermore, the similarity of HIF-driven tumors to classic
oncogene-driven malignancies suggests that RCCs may
similarly have exquisite sensitivity to DNA-damaging chemo-
therapeutic agents,22,23 justifying our ongoing research
targeting the DNA repair pathway in this disease (see below).
Given these fascinating and important signaling altera-
tions seen in RCC, this disease is ripe for the investigation of
tailor-made molecular targeting therapies, as will be dis-
cussed below following a brief exposition on conventional
treatment.
CONVENTIONAL TREATMENT
In the past, biopsies of kidney tumors were not routinely
performed since such procedures often missed the tumor and
thus did not exclude the presence of a malignancy. Lesions
with characteristics of renal masses were generally removed
without further work-up. There was also a theoretical
concern that malignant cells could be ‘track seeded’ by the
biopsy needle and thus lead to the spread of tumor cells.
However, with the advent of much improved imaging
techniques, which are utilized during modern biopsy
procedures, these concerns have largely been discredited.24
Thus, if there is a question as to whether a small renal mass is
truly a malignancy, biopsy should be considered before
nephrectomy or partial nephrectomy, especially in elderly
patients who present higher surgical risks.
Once the RCC has been identified, the conventional
treatment or patients with two functioning kidneys is
unilateral radical nephrectomy. This approach is quite
satisfactory for localized disease, but in the case of those
25–30% of patients presenting with regional or distant
metastases, the prognosis is poor, as discussed above. While
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Figure 3 | The hypoxia-regulated gene pathway. Under normoxic
conditions, HIF is complexed to pVHL, leading to its ubiquitization
and proteosome-mediated degradation. Chronic hypoxia (which can
be experimentally mimicked by deferoxamine (DFO)) causes VHL to
dissociate from HIF, causing HIF-1a stabilization, translocation to the
nucleus and transcription of key hypoxia genes leading to translation
of effector proteins. VHL mutant kidney cancers thus behave as
though they are hypoxic, although they are not. pVHL is inactive or
missing in these cells, causing HIF-1a to avoid degradation, resulting
in constitutively stable HIF-1a and continuous production of hypoxia
proteins, leading to exuberant angiogenesis and a ‘healthy’ tumor.
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partial nephrectomy (also known as ‘cytoreductive’25 or
‘nephron-sparing’ surgery) had been considered the standard
of therapy in patients presenting with higher stage disease, it
has now become apparent that perhaps this procedure should
not be carried out routinely on all patients. Nephron-sparing
surgery is increasingly favored by urologists as an alternative
to radical nephrectomy for the subset of patients with biopsy-
proven, smaller (o4 cm) RCCs, given new data on its
comparable long-term tumor control rate and preservation of
renal function.26 Other considerations, such as the stress of
surgery in high-risk patients and the consideration of initial
therapy prior to surgery, should be made before considera-
tion of radical vs partial nephrectomy. While the majority of
patients with metastatic RCC are surgical candidates on initial
diagnosis, in some situations the delay associated with
nephrectomy may result in clinical deterioration, which then
precludes systemic therapy;27 in these cases, medical therapy
should be initiated without delay even with the tumor in place.
There is a school of thought that ‘active surveillance’ or
watchful waiting, with delayed therapy reserved for those
patients whose disease progresses, might become the
standard of care in patients with renal masses o4 cm.28 This
experimental approach, based on preliminary studies in a
small cohort of elderly patients, should be considered for
older patients or for those with surgical comorbidities, but
these data need to be confirmed by a larger study before it
can be generally recommended.
The mainstay of conventional pharmacologic treatment
relies on immune-modulating approaches utilizing interferon
(IFN) and interleukin (IL)-2. There have been few phase 3
randomized studies, although there are many phase 2 studies
with small patient numbers. IFN-a, administered as a single
agent, gave a response rate of between 8 and 26%, with only
one-third of these responses being complete remissions.29–33
The median overall survival with IFN-a therapy is a dismal
13 months, and responses were most frequently seen in lung
metastases and less so in lymph nodes.
Standard treatment of metastatic RCC at the National
Cancer Institute has involved high-dose IL-2-based regi-
mens.27 IL-2 when used alone shows similar statistics to
IFN-a, with a response rate between 7 and 23%, one-third
being complete remissions.34–37 Toxic side effects, although
dependent on the dose and schedule of administration, are
higher with IL-2 than IFN-a.32 Caution should be exercised
with the use of IL-2 in patients with cardiovascular disease or
compromised renal function. The median overall survival
with IL-2 therapy was 12 months. Thus, it can be seen that
the success of the two mainstays of conventional treatment
are by no means satisfactory.
As far as other conventional agents are concerned, there is
some evidence that the combination of gemcitabine and
5-fluorouracil might have some activity against RCC, but
there are no available randomized studies to support this.38
The combination of IFN-a and IL-2 has also been
investigated. In a phase 3 trial of this regimen, disease-free
survival was higher in the combination arm, yet the overall
survival among the three groups was not different.39 Various
cytostatic chemotherapy agents alone and in combination,
as well as hormonal manipulation, have all shown no benefit
to survival and are thus not generally utilized (reviewed in
De Mulder et al.40).
INVESTIGATION OF NOVEL THERAPIES
There are several novel and exciting therapies on the horizon,
which have the potential for treatment of metastatic RCC and
may eventually lead to improvement in the current dreary
survival statistics. Many of these therapies target molecular
pathways that have already been worked out in this disease
(such as angiogenesis and the VHL pathways) or for which there
is a theoretical basis for their success but limited data (such as
the cyclin kinase inhibitors and PTEN (phosphatase and tensin
homologue deleted on chromosome 10) pathways) (Table 2).
VEGF INHIBITORS
Owing to the unique HIF-related molecular biology of
kidney cancer involving increased VEGF expression, as
discussed above, the targeting of the angiogenesis pathway
for therapy is a logical choice. Indeed, the most promising
‘designer drug’ therapies, so far, have targeted VEGF or its
receptor. A phase 2 trial of bevacizumab, a humanized
monoclonal-neutralizing antibody against VEGF, showed
promising results.41 In this study, which enrolled patients
Table 2 | Novel therapies and molecular targets with potential in RCC treatment
Target Therapeutic agent Purported mechanism Clinical status, ref.
VEGF Bevacizumab (Avastin) Humanized antibody to VEGF Phase 2/341,42
VEGFR1, VEGFR2 VEGF trap Receptors fused to IgG1-Fc Phase 1/279
Raf, VEGF, PDGF BAY 43-9006 Kinase inhibitor Phase 280
VEGFR2, PDGFR, c-Kit, Fms-like tyrosine kinase 3 SU11248 Tyrosine kinase inhibitor Phase 2/347
Bcr/Abl, PDGFR, c-Kit STI-571 (Gleevec, imatanib) Tyrosine kinase inhibitor Phase 2/381
EGFR ZD1839 (Iressa) Tyrosine kinase inhibitor Phase 2/348
EGFR OSI-774 (Tarceva, erlotinib) Tyrosine kinase inhibitor Phase 2/382,83
EGFR C-225 (Erbitux, Cetuximab) Humanized Ab to EGFR Phase 2/384,85
HIF-1 Topotecan, others Topoisomerase I poison Preclinical61,67,68
Small molecule inhibitors Preclinical71
p21 Antisense oligo- Promote apoptosis after DNA damage Preclinical56,73
RAD001 (everolimus)
EGFR, epidermal growth factor receptor; HIF-1, hypoxia-inducible factor; PDGF, platelet-derived growth factor; VEGF, vascular endothelial growth factor.
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with clear-cell RCC who had both metastatic disease and
documented progression, bevacizumab prolonged overall
survival, but there was no significant improvement in
survival. A pilot study using 22 patients from an earlier
phase 1 study showed no difference in progression-free
survival between bevacizumab alone and bevacizumab plus
thalidomide in metastatic RCC.42 A randomized, placebo-
controlled trial, using bevacizumab in combination
with irinotecan, bolus fluorouracil, and leucovorin (IFL)
or IFL alone, in advanced colorectal cancer, showed
statistically significant improvement in progression-free
survival in the bevacizumab arm.43 Currently, a phase 3 trial
of IFN-a or IFN-a plus bevacizumab in metastatic RCC is
underway.44
In an attempt to boost the efficacy of bevacizumab, several
investigators have attempted to combine it with erlotinib, a
small molecule inhibitor of the epidermal growth factor
receptor (see below about kinase inhibitors). These data,
which was presented in a meeting and, as of this writing, has
yet to be published in a peer-reviewed journal, came out of a
multicenter phase 2 study. In this study, 40 patients were
evaluated after 8 weeks of therapy and 10 of 40 (25%) showed
a partial response, six (15%) demonstrated a minor response,
19 patients (47%) showed stable disease and five (12%)
showed progression. These results were better than the
expected responses from either drug when used alone
(o10% partial response rate) and suggest a synergistic
salutary interaction of these drugs.
Owing to the fact that RCCs are angiogenic, a trial of
thalidomide was also undertaken. While thalidomide is a
potent angiogenesis inhibitor in vivo, there was no effect in
metastatic RCC in a phase 2 trial.45 In addition, arsenic
trioxide, which showed an apoptotic effect in other cancers,
showed no effect in a small phase 2 trial of metastatic RCC.46
KINASE INHIBITORS
Many growth factor receptors require phosphorylation on
tyrosine residues by the so-called ‘tyrosine kinases’ in order
for them to become activated and convey their signals to the
cellular replicative machinery. Therefore, identification of
synthetic kinase inhibitors, which affect those growth factor
receptors constitutively activated in specific malignancies, is
an area of great interest.
The drug SU11248 is an inhibitor of both VEGF and
PDGF receptors, which are know to be activated by the HIF
pathways described above, as well as the receptor tyrosine
kinases Kit and Fms-like tyrosine kinase 3. In a current phase
2 study of this drug, 63 patients with metastatic RCC who
had failed standard therapy received SU11248. Twenty-one of
them (33%) showed a partial response to the drug and
another 40% showed disease stabilization. Six months later,
the SU11248 response has persisted in some patients, and 14
of the responders continue on treatment with an ongoing
partial response. The drug is taken orally and is generally well
tolerated, with patients experiencing mild to moderate side
effects.
BAY 43-9006 (Sorafenib) is a kinase inhibitor that had
been originally developed against Raf, but was recently also
found to inhibit other receptor tyrosine kinases such as
VEGF and PDGF, thus its likely activity in RCC. A
randomized discontinuation trial was performed in 484
cancer patients, of whom 106 had kidney cancer. In this
study, all patients were treated with 400 mg of BAY 43-9006,
and those who had a 25% or greater reduction in tumor size
(‘stable’ disease) were randomly assigned to BAY 43-9006 or
placebo. Of these 37 patients, 88% were progression free at 6
months. However, the randomized arm is still blinded, so it is
not yet known who are on drug or placebo.47
A phase 2 trial of the specific epidermal growth factor
receptor tyrosine kinase inhibitor ZD1839 (Iressa) showed no
benefit at the dose and schedule used.48 However, as
mentioned above, another epidermal growth factor-receptor
inhibitor (erlotinib) showed synergy with bevacizumab,
suggesting that at least some receptor tyrosine kinase
inhibitors, while having minimal effect when used alone,
may be useful when combined with other inhibitors.
RAPAMYCIN
The mammalian target of rapamycin (mTOR) inhibitors are
proving to be an exciting new area of investigation for several
malignancy issues.49 Rapamycin and analogs form complexes
with FK-binding protein-12, which binds with high affinity
to mTOR, which subsequently causes inactivation of p70S6
kinase and thereby inhibits the production of ribosomal
components and proteins responsible for cell cycle progres-
sion.50 While such global effects may be expected to be
nonspecifically harmful, this has not been shown to be the
case. Furthermore, as the transplant community is aware,
rapamycin and its analogs show considerable promise as
immunosuppressive agents as they actually inhibit the risk of
cancer development due to loss of immune surveillance, in
contradistinction to cyclosporin A.51
The gene encoding PTEN is frequently deleted or mutated
in RCC such that its activity is lost.52,53 In PTEN-mutated
cells, increased phosphatidylinositol 3,4,5-trisphosphate le-
vels result in constitutively activated Akt, which itself lies
upstream of mTOR. Thus, the mTOR inhibitors may be
ideally suited for use in RCC. In an animal xenograft model
of p53 and phosphatase-dephosphorylating phosphatidyl-
inositol 3,4,5-trisphosphate mutant 786-O RCCs, rapamycin
was shown to inhibit the number of pulmonary metastases.54
(In the same study, cyclosporin A increased pulmonary
metastases.) In a phase 2 study using multiple doses of the
mTOR inhibitor CCI-779, performed in 111 patients with
advanced, refractory RCC, there was an objective response in
7% and minor response in 26%, with a median survival of 15
months (compared to a median survival ofo10 months with
conventional immunotherapy41), and the drug was well
tolerated.55 Another analog of rapamycin, RAD001, sensi-
tized human lung carcinoma cells to cisplatin-induced
apoptosis by inhibiting p21 translation,56 a finding consistent
with our work on the antiapoptotic effect of p2157 (and see
Kidney International (2006) 69, 224–232 229
RH Weiss and P-Y Lin: Kidney cancer targets r e v i e w
below). Based on these and other studies, mTOR inhibitors
need to be further studied in this disease, especially in
transplant patients at risk of recurrence of RCC.
HIF INHIBITORS
Since, as discussed above, it has now been established that
HIF is intimately involved in the ‘success’ and progression of
RCC, it is logical to target this protein for therapeutic gain.
The problem in RCC is constitutive activation of HIF due to
lack of degradation (see Figure 3), so, the solution is to target
this protein for degradation or, otherwise, inhibit its
activation. There exist a plethora of nonspecific pharmaco-
logical HIF-1 inhibitors, which were initially designed as
inhibitors of other cancer-relevant pathways. One of these
pathways is the phosphatidylinositol 30 kinase signaling
cascade, which is of special interest in RCC due to the
frequent inactivation of PTEN in these tumors, resulting in
constitutive activation of phosphatidylinositol 30 kinase and
subsequent stimulation of both growth-promoting and
apoptotic pathways (discussed above). Inhibitors of phos-
phatidylinositol 30 kinase, such as wortmannin, have shown
the expected HIF inhibitory beneficial results in vitro58 but
there are limited studies reporting in vivo utility of this
agent.59,60 The mTOR pathway, which lies downstream of
phosphatidylinositol 30 kinase, has also been a target for HIF
as shown by the exciting efficacy of mTOR inhibitors in this
disease, as has been discussed above.
Heat-shock protein 90 is a molecular chaperone crucial for
proper folding of HIF-1a; inhibition of this protein by
geldanamycin has shown inhibitory action toward HIF-1a.61
Owing to the findings that the signaling proteins Ras,62 Src,63
and Rho64 have been shown to be important in HIF function,
it is likely that the statins, which inhibit farnesylation and
thus membrane localization of these proteins,65 might have a
salutary effect in this disease as has been shown in one
study.66 Other HIF inhibitors, including the topoisomerase I
inhibitors (topotecan)67 and microtubule-modifying agents
(2-methoxyestradiol, taxol, and vincristine),68 have shown
promise in early studies. The concept of screening combina-
torial libraries for small molecule inhibitors of HIF are
certain to lead to promising compounds; such reports are
now beginning to appear in the literature and will require
further evaluation.69,70 In one of these cases, a collection of
B2000 compounds in a National Cancer Institute repository
yielded three of a total of four HIF-1 inhibitors that were in
the topoisomerase I inhibitor family.71
CYCLIN KINASE INHIBITORS AND TUMOR TARGETING
The fidelity of DNA replication during cell cycle transit is
precisely controlled by proteins comprising the p53 pathway.
In fact, p53 is the most commonly mutated gene in human
cancer, a finding which attests to its importance. The
function of p53 is to integrate cellular stress and DNA
damage signals into the downstream decision tree of cell cycle
arrest or apoptosis.57 p53 is therefore referred to as the
‘guardian of the genome’ because it preserves genomic
integrity by removing cells with defective DNA (by
apoptosis) from the pool of somatic replicating cells. For
this reason, individuals with p53 mutations are at very high
risk for a variety of cancers. A principal downstream effector
of p53 is p21, which has an antiapoptotic function that allows
cells with damaged DNA to survive while repairs to their
DNA can be made.57 However, this same mechanism, which
is beneficial in the case of normally dividing cells, can also
result in chemotherapy failure by allowing cells with DNA
damage, as by chemotherapy, to repair. In this manner, p21
can contribute to tumor progression,72 such that attenuation
of this protein has a potential in the treatment of a variety of
malignancies73,74 (Figure 4). We have recently shown that p21
has prognostic value in clear-cell RCC as a function of
whether the tumors are localized or metastatic at resection
(RH Weiss, AD Borowsky, D Seligson, P-Y Lin, AS
Belldegrun, RA Figlin, AD Pantuck, manuscript submitted).
These data suggest that intrinsic molecular differences exist
between some localized and metastatic forms of clear-cell
RCC and underlie the differences in their biologic behavior,
as has been suggested by gene array analysis75. These
differences could potentially be exploited in utilizing current,
as well as designing future, therapeutic options. Research
involving p21 attenuation in RCC, promising in the light of
both the basic56 and clinical55 mTOR inhibitor data
published recently, is ongoing in our laboratory. Identifica-
tion of novel small molecule inhibitors of p21, which may
function to foil the DNA repair pathway after conventional
chemotherapy, is also currently being investigated in our
laboratory.
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cancer cell
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damage of
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Figure 4 | A scenario for the use of p21 attenuators to enhance
chemotherapeutic efficacy. Depending on the severity of DNA
damage, response to a chemotherapeutic agent will be either
apoptosis (an ineffective drug) or successful repair (drug resistance).
Based on the current knowledge of p21 as an antiapoptotic protein, it
is conceivable that transient attenuation of p21 concomitant with
DNA-damaging chemotherapy, such as with antisense techniques or
small molecule inhibitors (purple shading), would improve the
efficacy, and thus decrease toxicity, of standard chemotherapeutic
agents (from Weiss,57 used with permission).
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Translating p21 antisense oligodeoxynucleotide or small
interfering RNA technology, or indeed any encapsulatable
therapeutic, into the clinic is made theoretically more feasible
by the occurrence of an antigen to the carbonic anhydrase IX
protein preferentially displayed on malignant tissue. G250 is a
VHL/HIF-regulated protein that is displayed on 485% of
clear-cell RCCs and is related to the seminal VHL tumor
suppressor mutation. It is not usually prominent in normal
tissues, which of course enhances its ultimate clinical utility,
and is probably the best-known surface molecule target in
kidney cancers. Several clinical studies, mostly using an 131I-
labeled monoclonal antibody against G250, have shown that
this is an excellent potential antigen to use in RCC
targeting;76,77 another recent study has explored the use of
recombinant human adenovirus targeted to this antigen.78
CONCLUSIONS
While the current treatment options for metastatic kidney
cancer are woefully inadequate, novel approaches are
currently being evaluated in a number of laboratories and
clinics. Although no treatment has yet been unequivocally
proven effective, it is likely that these therapies, which are
based on the recently elucidated oncogenic pathways, will
soon lead to substantial advances in this field and may soon
alter the current accelerating trend of this disease.
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